PhRMA President Introduces Recipients of 2020 Challenge Award, Emphasizes Commitment to Patient Centricity
The PhRMA Foundation has expanded its vision of the value assessment framework to include health equity and patient centricity. PhRMA [...]
Democrats’ Pricing Legislation Insufficient; PhRMA’s Criticism of Policies Unwarranted
Attempts to reduce drug costs via policy changes are insufficient. Despite the relatively small scale of new legislation, including allowing [...]
PhRMA Proposes Multi-Pronged Solutions to Drug Affordability Crisis
The Pharmaceutical Research and Manufacturers of America (PhRMA) discussed several solutions that would reduce healthcare costs for patients while maintaining [...]
PhRMA Seeks to Address Health Disparities and COVID-19 Impact, Awards $150,000 in Community-Level Grants
PhRMA has announced four health disparity initiatives that will receive a quarter of $150,000. The programs tackle COVID-19 vaccine hesitancy, [...]
PhRMA’s 2021 Biopharmaceutical Industry Profile Now Available
PhRMA has published this year’s Biopharmaceutical Profile. The report highlights key industry trends, such as prescription drug pricing policy measures, [...]
PhRMA President Discusses Patient Centricity in Value Assessments
President of Pharmaceutical Research and Manufacturers of America (PhRMA) Foundation Eileen Cannon shared her thoughts on adding a patient-centered component [...]
Pharma and Patient Advocacy Groups Release Expensive Ads Ahead of Drug Price Negotiation Bill
Patient and prescription drug pricing advocacy groups, including Patients for Affordable Drugs Now, are pushing for drug legislation using expensive [...]
Researchers Claim Drug Price Limits Won’t Impact Innovation, PhRMA Strongly Disagrees
In a recently published article, researchers at Bentley University and West Health conclude that limiting drug prices will not affect [...]
PhRMA President and CEO Discusses Lowering Prescription Drug Prices Using Patient-Centered Medicare Legislation
PhRMA CEO and President Stephen Ubl discusses how new Medicare legislation could impact consumers at a time when patients continue [...]
Astellas US President Discusses Improving Medication Affordability, Patient-Centered Care, and Learning From COVID-19 Challenges
PhRMA board member and Astellas US President Mark Reisenauer shares his thoughts on improving the healthcare system in the United [...]
PhRMA Sues Federal Government Regarding Medicaid Best Price Ruling
The Pharmaceutical Research and Manufacturers of America (PhRMA) group has sued the Department of Health and Human Services. PhRMA is [...]
West Virginia Takes Legislative Action to Lower Drug Costs, Improve Health Equity
West Virginia passed a law that will compel payers and PBMs (Pharmacy Benefit Managers) to pass on medication savings to [...]
PhRMA Kicks Off New Agenda, Including Endorsement of Drug Pricing Reforms
National lobbying group PhRMA introduced a new agenda this week with a pointed message at the White House: pharma has [...]
Research Suggests Pharma Retains Lowest Share of Revenue than Other High R&D Industries
Oxford Economics in a new study suggests the pharmaceutical industry only retains 52 percent of total spending, with the remaining [...]
PhRMA: PBMs Hamper Access with Expanded Exclusion Lists
In a recent blog post, PhRMA says CVS Caremark and Express Scripts have hampered patient access to a number of [...]
Retail Medicine Spending Expected to Remain Stable
New projections from the Centers for Medicare & Medicaid Services (CMS) suggest retail medicine spending will remain stable through the [...]
PhRMA: HCCI Report ‘Overestimates Medicine Spending and Pricing’
The Health Care Cost Institute's (HCCI) recent report on health spending "overestimates medicine spending and pricing and mischaracterizes the true [...]
PhRMA Announces HEOR Funding Opportunities
The PhRMA Foundation announced it is accepting applications for up to $100,000 in fellowships and grants for health outcomes research. [...]
Report: Pharma Spent $120M on Lobbying Last Year
New federal disclosures revealed that 34 major pharmaceutical companies spent more than $120 million on lobbying last year, STAT reports. [...]